Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: Data from the Italian registry

M. Martino, A. Ballestrero, A. Zambelli, S. Secondino, M. Aieta, C. Bengala, A. M. Liberati, C. Zamagni, M. Musso, M. Aglietta, R. Schiavo, L. Castagna, G. Rosti, B. Bruno, P. Pedrazzoli

Research output: Contribution to journalArticlepeer-review

Abstract

The median survival of women with metastatic breast cancer (MBC) is 18-24 months, and fewer than 5% are alive and disease free at 5 years. We report toxicity and survival in a cohort of MBC patients receiving high-dose chemotherapy (HDC) with autologous hematopoietic SCT (AHSCT) in Italy between 1990 and 2005. Data set for survival analysis has been obtained for 415 patients. Clinical parameters including probability of transplant-related mortality (TRM), PFS and OS. With a median follow-up of 27 months (range 0-172), OS and PFS at 5 and 10 years in the whole population were 47/23 and 32/14%, respectively. A total 239 patients are alive with a median follow-up of 33 months (range 2-174). Survival was significantly more pronounced in patients harboring hormone receptor positive tumors (P=0.028), without visceral metastases (P=0.009) and in women with chemosensitive disease (P

Original languageEnglish
Pages (from-to)414-418
Number of pages5
JournalBone Marrow Transplantation
Volume48
Issue number3
DOIs
Publication statusPublished - Mar 2013

Keywords

  • intensified chemotherapy
  • metastatic breast cancer
  • stem cell transplantation
  • toxicity; survival

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: Data from the Italian registry'. Together they form a unique fingerprint.

Cite this